Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Element Biosciences | San Diego | Series E | $277.0M | 2026-06-09 |
| Gameto | New York | Series C | $44.0M | 2025-08-12 |
| Claris Biotherapeutics | Jersey City | Series B | $118.0M | 2026-07-28 |
| ADCendo | Copenhagen | Series C | $75.0M | 2026-04-14 |
| Terrestrial Bio | Cambridge | Series C | $50.0M | 2026-03-26 |
| Capstan Therapeutics | San Diego | Series B | $175.0M | 2024-03-20 |
| Superluminal Medicines | Boston | Series B | $65.5M | 2026-09-03 |
| Alchemab Therapeutics | London | Series A | $33.6M | 2026-07-09 |
8 rows of the CSV in 5 of its 18 columns.
- The 47 RA Capital Management portfolio companies have raised $9.9B in total.
- 9 of them closed their most recent round in the last 12 months, $1.1B combined.
- The largest of those rounds is Element Biosciences' $277.0M Series E, dated June 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- OrbiMed is an investor in 10 of them, more than any other fund.
- Health care is the most common sector, with 46 companies (98%).
- 34% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 11 to 50 employees (47% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 47| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston, United States | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston, United States | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego, United States | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge, United States | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown, United States | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| Adcytherix | Adcytherix is a biopharmaceutical firm developing antibody drug conjugates. | Biotech | Marseille, France | Series A | $122.8M | 2025-10-16 | $155.1M | RA Capital Management, Pureos Bioventures, Pontifax +1 | 11 to 50 | 2023 |
| TORL BioTherapeutics | TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. | Biotech | Culver City, United States | Series C | $96.0M | 2025-10-07 | $412.0M | Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 | 51 to 100 | 2018 |
| Gameto | Gameto develops cell-engineered therapeutics for the female reproductive system. | Biotech | New York, United States | Series C | $44.0M | 2025-08-12 | $117.0M | FJ Labs, Insight Partners, Gaingels +2 | 11 to 50 | 2020 |
| Verdiva Bio | Verdiva Bio develops treatments for patients with obesity and cardiometabolic diseases. | Biotech | London, United Kingdom | Series A | $411.0M | 2025-01-09 | $411.0M | General Atlantic, RA Capital Management, OrbiMed +1 | 11 to 50 | 2024 |
| Alentis Therapeutics | Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. | Biotech | Allschwil, Switzerland | Series D | $181.4M | 2024-11-12 | Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 | 51 to 100 | 2019 | |
| Trace Neuroscience | Trace Neuroscience aims to extend the promise of genetic medicine to patients. | Biotech | South San Francisco, United States | Series A | $101.0M | 2024-11-12 | $101.0M | RA Capital Management, Atlas Venture, Third Rock Ventures | 11 to 50 | 2024 |
| Convergent Therapeutics | Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer. | Health care | Cambridge, United States | Series A | $40.0M | 2024-09-24 | $130.0M | RA Capital Management, OrbiMed, Invus | 1 to 10 | 2021 |
| Halda Therapeutics | Halda Therapeutics is a research-stage drug discovery company. | Biotech | New Haven, United States | Series B | $126.0M | 2024-08-12 | $208.3M | Canaan Partners, RA Capital Management, Connecticut Innovations +2 | 11 to 50 | 2018 |
| MBX Biosciences | MBX Biosciences is a preclinical biotech company creating therapies for rare endocrine diseases. | Biotech | Carmel, United States | Series C | $63.5M | 2024-08-05 | $238.4M | New Enterprise Associates, RA Capital Management, OrbiMed +2 | 11 to 50 | 2019 |
| AltruBio | AltruBio develops targeted antibody therapeutics for cancer and immune-related inflammatory diseases. | Biotech | Los Altos, United States | Series B | $225.0M | 2024-05-21 | $327.6M | RA Capital Management, Blackstone, Cormorant Asset Management +2 | 11 to 50 | 2000 |
| Bluejay Therapeutics | Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. | Biotech | San Mateo, United States | Series C | $182.0M | 2024-05-09 | $242.2M | RA Capital Management, Wellington Management, Novo Holdings +2 | 11 to 50 | 2019 |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | San Diego, United States | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| Sionna Therapeutics | Sionna Therapeutics develops small molecule therapies for treating cystic fibrosis. | Biotech | Natick, United States | Series C | $182.0M | 2024-03-06 | $292.0M | RA Capital Management, OrbiMed, T. Rowe Price +2 | 11 to 50 | 2018 |
| Aiolos Bio | Aiolos Bio is a biotech company developing therapies for respiratory diseases and immune conditions. | Biotech | San Francisco, United States | Series A | $245.0M | 2023-10-24 | $245.0M | RA Capital Management, Atlas Venture, Forbion Capital Partners +2 | 11 to 50 | 2023 |
| Rampart Bioscience | Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. | Biotech | La Jolla, United States | Series A | $85.0M | 2023-10-24 | $85.0M | RA Capital Management, OrbiMed, Forbion Capital Partners +1 | 11 to 50 | 2019 |
| Hyku | Hyku develops covalent drugs that precisely target disease-causing proteins. | Biotech | Lexington, United States | Seed | $56.0M | 2023-09-19 | $56.0M | KB Investment, RA Capital Management, Novartis Venture Fund +2 | 11 to 50 | 2021 |
| Mariana Oncology | Mariana Oncology conducts biotechnology research in the oncology field. | Biotech | Watertown, United States | Series B | $175.0M | 2023-09-07 | $250.0M | RA Capital Management, Forbion Capital Partners, Surveyor Capital +1 | 11 to 50 | 2021 |
| Metagenomi | Metagenomi uses metagenomics and machine learning to discover genome editing systems for therapeutics. | Artificial intelligence | Emeryville, United States | Series B | $100.0M | 2023-01-05 | $466.7M | RA Capital Management, Bristol-Myers Squibb, Marshall Wace +1 | 101 to 250 | 2018 |
| Empatica | Empatica develops affective computing technology and human data analytics. | Artificial intelligence | Cambridge, United States | Series B | $25.9M | 2022-08-02 | $35.6M | Bossa Invest, Endeavor Catalyst, RA Capital Management +2 | 101 to 250 | 2011 |
| CDR-Life AG | CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. | Biotech | Schlieren, Switzerland | Series A | $76.0M | 2022-04-13 | $76.0M | RA Capital Management, Omega Funds, Jeito Capital | 51 to 100 | 2017 |
| Synthego | Synthego provides genome engineering services and CRISPR tools for life science research. | Artificial intelligence | Redwood City, United States | Series E | $200.0M | 2022-02-17 | $459.7M | Intel Capital, Founders Fund, Menlo Ventures +2 | 101 to 250 | 2012 |
Table 1. RA Capital Management portfolio companies: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 47.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego, United States | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| 2 | CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| 3 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown, United States | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 4 | Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| 5 | Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston, United States | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| 6 | ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| 7 | Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston, United States | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| 8 | Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge, United States | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| 9 | Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
Table 2. RA Capital Management portfolio companies: the 9 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed | Private equity firm | New York, United States | 10 | 21% | ||
| 2 | T. Rowe Price | Private equity firm | Baltimore, United States | 6 | 13% | 1 | Element Biosciences |
| 3 | Wellington Management | Private equity firm | Boston, United States | 5 | 11% | 1 | Element Biosciences |
| 4 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 5 | 11% | ||
| 5 | Fidelity | Investment bank | Boston, United States | 4 | 9% | 1 | Element Biosciences |
| 6 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 3 | 6% | 2 | Claris Biotherapeutics, ADCendo |
| 7 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 3 | 6% | ||
| 8 | Invus | Private equity firm | New York, United States | 3 | 6% | ||
| 9 | Atlas Venture | Venture capital firm | Cambridge, United States | 3 | 6% | 1 | Diagonal Therapeutics |
| 10 | Deep Track Capital | Hedge fund | Greenwich, United States | 3 | 6% | ||
| 11 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 3 | 6% | ||
| 12 | Insight Partners | Private equity firm | New York, United States | 2 | 4% | 1 | Superluminal Medicines |
| 13 | Gaingels | Syndicate | Burlington, United States | 2 | 4% | 1 | Delix Therapeutics |
| 14 | Pontifax | Venture capital firm | Herzliya, Israel | 2 | 4% | 1 | ADCendo |
| 15 | HealthCap | Venture capital firm | Stockholm, Sweden | 2 | 4% | 1 | ADCendo |
Table 3. RA Capital Management portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 46 | 98% | $9.9B |
| Biotech | 42 | 89% | $9.4B |
| Software | 7 | 15% | $1.8B |
| Artificial intelligence | 6 | 13% | $1.5B |
| Hardware | 1 | 2% | $35.6M |
Table 4. RA Capital Management portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. RA Capital Management portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 37 | 79% |
| United Kingdom | 3 | 6% |
| Switzerland | 3 | 6% |
| Germany | 2 | 4% |
| Denmark | 1 | 2% |
| France | 1 | 2% |
Table 6. RA Capital Management portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Cambridge | 7 | 15% |
| San Francisco | 4 | 9% |
| San Diego | 2 | 4% |
| New York | 2 | 4% |
| Boston | 2 | 4% |
| London | 2 | 4% |
| Watertown | 2 | 4% |
| Redwood City | 2 | 4% |
| Allschwil | 2 | 4% |
| Seattle | 2 | 4% |
| Jersey City | 1 | 2% |
| Copenhagen | 1 | 2% |
Table 7. RA Capital Management portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 11% | $100.0M |
| September 2026 | 1 | 11% | $65.5M |
| July 2026 | 2 | 22% | $151.6M |
| June 2026 | 1 | 11% | $277.0M |
| May 2026 | 1 | 11% | $220.0M |
| April 2026 | 1 | 11% | $75.0M |
| March 2026 | 1 | 11% | $50.0M |
| January 2026 | 1 | 11% | $125.0M |
Table 8. RA Capital Management portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 9 | 19% | $1.1B |
| 2025 | 5 | 11% | $673.8M |
| 2024 | 18 | 38% | $2.1B |
| 2023 | 9 | 19% | $902.2M |
| 2022 | 3 | 6% | $301.9M |
| 2021 | 3 | 6% | $218.1M |
Table 9. RA Capital Management portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 4 | 9% |
| 2020 to 2022 | 12 | 26% |
| 2015 to 2019 | 24 | 51% |
| 2010 to 2014 | 4 | 9% |
| Before 2010 | 3 | 6% |
Table 10. RA Capital Management portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 6 | 13% |
| 11 to 50 | 22 | 47% |
| 51 to 100 | 10 | 21% |
| 101 to 250 | 8 | 17% |
| 251 to 500 | 1 | 2% |
Table 11. RA Capital Management portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when RA Capital Management is recorded as one of its investors. On 16 November 2026 that is 47 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 47 rows: 1 have no round amount, 0 no city and 1 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many RA Capital Management portfolio companies are on the list?
- 47, in the file dated 16 November 2026. 9 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 47 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.